There are 2949 resources available
759P - Towards personalized medicine in MIBC: Immunohistochemistry-based taxonomical classification and outcome in patients treated with adjuvant chemotherapy
Presenter: Daniel Castellano Gauna
Session: E-Poster Display
Resources:
Abstract
760P - Platinum-based adjuvant chemotherapy in upper tract urothelial carcinomas (UTUCs): A change of paradigm? A meta-analysis of aggregate data
Presenter: Angela Dalia Ricci
Session: E-Poster Display
Resources:
Abstract
761P - Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer. NEODURVARIB trial
Presenter: Juan Rodriguez-Moreno
Session: E-Poster Display
Resources:
Abstract
762P - Molecular profiling of post-pembrolizumab muscle-invasive bladder cancer (MIBC) reveals unique features that may inspire new sequential therapies in pathologically-nonresponders
Presenter: Andrea Necchi
Session: E-Poster Display
Resources:
Abstract
763P - The influence of multidisciplinary team meetings on treatment decisions in muscle invasive bladder cancer: A nationwide study in the Netherlands
Presenter: Janneke Walraven
Session: E-Poster Display
Resources:
Abstract
764P - Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: Longitudinal expression, transcriptome-level effects and modulation of chemosensitivity
Presenter: Sara Wahlin
Session: E-Poster Display
Resources:
Abstract
765P - Predicting survival in urothelial cancer patients after immunotherapy using real-world data
Presenter: Thiraviyam Elumalai
Session: E-Poster Display
Resources:
Abstract
766P - Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study
Presenter: Michal Mego
Session: E-Poster Display
Resources:
Abstract
768P - Prognostic score combining systemic inflammation index (SII) and PD-L1 +/- LDH in advanced urinary tract carcinoma patients treated with atezolizumab: Subanalysis in the Italian population of the SAUL study
Presenter: Sara Elena Rebuzzi
Session: E-Poster Display
Resources:
Abstract
767P - Neutrophil-to-lymphocyte ratio (NLR) and systemic inflammation index (SII) as prognostic factors in advanced urinary tract carcinoma patients treated with atezolizumab: Subanalysis of the Italian population of the SAUL study
Presenter: Sara Elena Rebuzzi
Session: E-Poster Display
Resources:
Abstract